Insights

Gathering insights about Caribou…

Similar companies to Caribou

Caribou Tech Stack

Caribou uses 8 technology products and services including Atlassian Jira, Angular, HubSpot Chat, and more. Explore Caribou's tech stack below.

Atlassian Jira
Issue Trackers
Angular
Javascript Frameworks
HubSpot Chat
Live Chat
GraphQL
Programming Languages
JavaScript
Programming Languages
reCAPTCHA
Security
ShareThis
Widgets
Facebook
Widgets

Media & News

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve r/r MM patient cohort -- -- Ongoing dose expansion enrollment in CaMMouflage phase 1 clinical trial includes BCMA-naïve and BCMA-exposed cohorts; initial dose expansion and longer follow up on dose escalation data expected in 2026 -- BERKELEY, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011 for relapsed or refractory multiple myeloma (r/r MM).
Mar 31, 2026 | www.globenewswire.com
Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value
Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety rivaling approved autologous products. CRBU trades near net cash value, implying the market assigns minimal value to its pipeline despite RMAT designation and promising Phase 1 results. Key risks include dilution, regulatory hurdles, and competition from in vivo CAR-T, but CRBU's CRISPR chRDNA editing and leadership provide strategic advantages.
Mar 17, 2026 | seekingalpha.com
Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference
Executives from Caribou Biosciences (NASDAQ: CRBU) outlined upcoming clinical, regulatory, and financing milestones for its allogeneic cell therapy pipeline during a discussion at the Leerink Global Healthcare Conference in Miami. Management focused on plans to advance its lead program, vispa-cel, into a pivotal study in second-line large B-cell lymphoma (LBCL) and provided updates on CB-011 in
Mar 16, 2026 | www.defenseworld.net
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.39 per share a year ago.
Mar 05, 2026 | www.zacks.com
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights.
Mar 05, 2026 | www.globenewswire.com
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.
Feb 20, 2026 | www.zacks.com
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample
BOULDER, Colo.--(BUSINESS WIRE)-- #NGS--Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, W.
Feb 17, 2026 | www.businesswire.com

Caribou's Email Address Formats

Caribou uses at least 1 format(s):

Caribou Email Formats	Example	Percentage
First@caribouwealth.com	John@caribouwealth.com	50%
First@caribouwealth.com	John@caribouwealth.com	50%

Frequently Asked Questions

Where is Caribou's headquarters located?

Caribou's main headquarters is located at San Francisco, California United States. The company has employees across 1 continents, including North America.

What is Caribou's stock symbol?

Caribou is a publicly traded company; the company's stock symbol is CRBU.

What is Caribou's official website and social media links?

Caribou's official website is caribouwealth.com and has social profiles on LinkedIn Crunchbase.

What is Caribou's NAICS code?

Caribou's NAICS code is 52 - Finance and Insurance.

How many employees does Caribou have currently?

As of March 2026, Caribou has approximately 28 employees across 1 continents, including North America. Key team members include Health Planning Coordinator: M. M.Health Plan Coordinator: C. M.. Explore Caribou's employee directory with LeadIQ.

What industry does Caribou belong to?

Caribou operates in the Financial Services industry.

What technology does Caribou use?

Caribou's tech stack includes Atlassian JiraAngularHubSpot ChatGraphQLJavaScriptreCAPTCHAShareThisFacebook.

What is Caribou's email format?

Caribou's email format typically follows the pattern of First@caribouwealth.com. Find more Caribou email formats with LeadIQ.

Caribou

Q: What is Caribou's official website and social media links?

Caribou's official website is caribouwealth.com. Caribou has social profiles on LinkedIn.

Q: How many employees does Caribou have currently?

Caribou has approximately 28 employees.

Q: What technology does Caribou use?

Caribou's tech stack includes HubSpot Analytics, jQuery, HubSpot, Hotjar, ShareThis.

Financial ServicesCalifornia, United States11-50 Employees

Caribou was successfully acquired by Move Health in January 2025.

Company Overview

Headquarters: San Francisco, California United States
Website: caribouwealth.com
Stock Symbol: CRBU
NAICS Code: 52 - Finance and Insurance
Employees: 11-50

Media & News

Funding & Financials

$1M
Caribou's revenue is estimated to be in the range of $1M

Funding & Financials

$1M
Caribou's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Caribou

myAutoloan.com

Credible

NerdWallet

Auto Credit Express

Caribou Tech Stack

Media & News

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates

Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Genomics Stocks That Deserve a Place in Your Portfolio in 2026

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Caribou's Email Address Formats

Frequently Asked Questions

Where is Caribou's headquarters located?

What is Caribou's stock symbol?

What is Caribou's official website and social media links?

What is Caribou's NAICS code?

How many employees does Caribou have currently?

What industry does Caribou belong to?

What technology does Caribou use?

What is Caribou's email format?

Caribou

Company Overview

Media & News

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Caribou Biosciences: Antlers Up For The Allogenic CAR-T Bet Trading At Cash Value

Caribou Biosciences Teases vispa-cel Phase 3 LBCL Plan, Eyes Financing at Leerink Conference

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?